Search clinical trials for: Selective estrogen receptor degrader

Total 20675 results

MedSIR
Stemline Therapeutics, Inc.

Not yet recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)

Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation
Hoffmann-La Roche

Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Belgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, H...
University of Miami

Recruiting

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Breast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer

United States
Zeno Alpha Inc.

Completed

A Study of ZN-c5 in Subjects With Breast Cancer

Breast Cancer

United States, Belarus, Bosnia and Herzegovina, Czechia, Hungary, Lithuania, Russian Federation, Serbia, Ukraine
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Healthy Subjects

United Kingdom
Zeno Alpha Inc.

Completed

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

Breast Cancer

United States, Poland
Astellas Pharma Global Development, Inc.

Not yet recruiting

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Hot Flashes
Roswell Park Cancer Institute

Not yet recruiting

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Unresectable Triple-Negative Breast Carcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

External Mastalgia-oil Versus Oral Tamoxifen in Premenopausal Women With Severe Mastalgia

Mastalgia

China
Andrea DeCensi
Herbert Irving Comprehensive Cancer Center; Breast Cancer Research Foundation; Istituto Europeo di Oncologia and other collaborators

Not yet recruiting

Babytam vs Babyexe in Post-menopausal Women at High Risk for Breast Cancer. (BabyTears)

Breast Cancer

Italy
Medical College of Wisconsin

Not yet recruiting

Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Breast Cancer

United States
Sohag University

Not yet recruiting

Maintenance Hormonal Therapy and DLBCL

Diffuse Large B Cell Lymphoma
International Research Training Group 2804
German Research Foundation; Uppsala University; University Hospital Tuebingen

Not yet recruiting

Breast Cancer & Antiestrogenic Therapy & Brain

Menopause | Breast Cancer Female | Healthy Female | Anti-estrogenic Therapy

Germany
University of Chicago

Not yet recruiting

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast Cancer | HER2-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
University of Nebraska

Not yet recruiting

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection (MCN_Tam)

Pancreatic Cyst | Pancreatic Mucinous Cystic Neoplasm

United States
Region Örebro County
Mid-Sweden Regional Cancer Centre; Akademiska University Hospital, Uppsala,...

Not yet recruiting

Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer (SWE-Switch)

Breast Cancer

Sweden
National Cancer Institute (NCI)

Not yet recruiting

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Breast Atypical Hyperplasia

United States
National Cancer Institute (NCI)

Not yet recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast Carcinoma

United States
Batterjee Medical College

Not yet recruiting

Cost-effective Treatment of Unexplained Infertility

Unexplained Infertility

Saudi Arabia
University of Washington
Breast Cancer Research Foundation

Not yet recruiting

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...

United States
DR. DIANE CHISESI NFS. MD. PHD.
IRB

Not yet recruiting

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor (NASBP-B-09)

Chronic Pain | Metastatic Breast Cancer | Tumor | Muscle Neoplasms

United States
QuantumLeap Healthcare Collaborative

Recruiting

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Ductal Carcinoma in Situ

United States
Guangzhou University of Traditional Chinese Medicine
University of Houston

Recruiting

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

Xiao Chai Hu Tang | Irinotecan-induced Diarrhea

China
European Institute of Oncology
Istituto Oncologico Veneto IRCCS; Ente Ospedaliero Ospedali Galliera; Istituto...

Not yet recruiting

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion (TOLERANT)

Ductal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA Mutation

Italy
Dana-Farber Cancer Institute
Eli Lilly and Company

Recruiting

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Breast Cancer | Early-stage Breast Cancer | High Risk Breast Carcinoma

United States
AstraZeneca
Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)

Breast Cancer, Early Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, Canada, Poland, Portugal, United Kingdom, France, China, Germany, Japan, Mexico, Thailand, Hungary, Australia, Austria, Brazil, Colombia, Taiwan, Malaysia, Philippines, Romania, ... and more
National Cancer Institute (NCI)

Not yet recruiting

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Breast Atypical Hyperplasia

United States
Fudan University

Recruiting

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

HR Positive HER2 Negative Advanced Breast Cancer

China
Neil Chappell

Not yet recruiting

Use of Clomiphene Citrate as an Inhibitor of Ovulation in an Oocyte Cryopreservation Cycle (CCOI)

Infertility | Infertility, Female

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Premenopausal Breast Cancer | Hormone-receptor-positive Breast Cancer | Breast Cancer Patients at Intermediate to High Risk | Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen

China
Blokhin's Russian Cancer Research Center

Recruiting

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia (NEMO)

Breast Cancer | Neoadjuvant Endocrine Therapy

Russian Federation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Breast Cancer

China
AstraZeneca

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

Breast Cancer, Early Breast Cancer

United States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
Bezmialem Vakif University

Recruiting

Comparison of Recombinant Follicle Stimulating Hormone and the Combination of Recombinant Follicle Stimulating Hormone With Clomiphene Citrate in Stimulated Intrauterine Insemination Cycles

Infertility Unexplained

Turkey
Sun Yat-sen University

Not yet recruiting

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy

Ovarian Cancer

China
MedSIR

Recruiting

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% (EMPRESS)

Breast Cancer | Breast Cancer, Early-Onset

Spain, France
Accutar Biotechnology Inc

Recruiting

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)

Advanced Breast Cancer

China, Japan, United States, Taiwan, Canada, Korea, Republic of, Spain, Bulgaria, Turkey, Finland, Italy, Czechia, India, Slovakia, South Africa, Germany, Australia, Brazil, Greece, Puerto Rico, Belgium, Argentina, Switzerland, Poland, ... and more
Erasmus Medical Center

Recruiting

Tamoxifen Prediction Study in Patients With ER+ Breast Cancer (PREDICTAM)

ER+ Breast Cancer

Netherlands
Eli Lilly and Company

Recruiting

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)

Breast Neoplasms

China, Japan, United States, Australia, Taiwan, Belgium, Canada, United Kingdom, Spain, France, Argentina, Ireland, Netherlands, Turkey, Czechia, Korea, Republic of, Finland, Hungary, Italy, Mexico, Brazil, Germany, India, Austria, Greece, Roman... and more
European Organisation for Research and Treatment...
Breast International Group; Menarini Group

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)

Stage IIB Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Stage III Breast Cancer

Belgium, Italy, Ireland, France, Germany
Jose Pablo Leone
Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC)

Recruiting

ETHAN - ET for Male BC

Male Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Negative Breast Carcinoma

United States
UNC Lineberger Comprehensive Cancer Center

Recruiting

Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) (CAMERAN)

Quality of Life | Breast Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Metastatic Breast Cancer

China
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
Treadwell Therapeutics, Inc

Recruiting

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

Breast Cancer | Advanced Solid Tumor

United States
Relay Therapeutics, Inc.

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Unresectable Solid Tumor | PIK3CA Mutation

United States, Spain, France, Italy
Sharif Medical Research Center

Recruiting

Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility

Male Infertility | Oligoasthenoteratozoospermia

Pakistan
Novartis Pharmaceuticals

Recruiting

Roll-over Study to Allow Continued Access to Ribociclib

Metastatic Breast Cancer

United States, Lebanon, Hong Kong, Turkey, Vietnam, Brazil, Italy, South Africa, Korea, Republic of, Poland, Taiwan, Singapore, Japan, Spain, Costa Rica, Greece, Portugal, Argentina, Mexico

Search clinical trials for: Selective estrogen receptor degrader

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations